Tag: follicular lymphoma

wo clinical trials testing the antibody loncastuximab tesirine (Zynlonta® ADC Therapeutics) showed encouraging results in the treatment of patients diagnosed with high-risk forms of two blood cancers – follicular lymphoma (FL) and marginal zone lymphoma (MZL).

The investigational drug TRPH-222 (previously known as CAT-02-106), a next-generation antibody-drug conjugate (ADC), is demonstrating early signs of efficacy in the interim results of...

Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...

A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...